PTHS Company Profile and Key Details

PTHS has shown weak momentum, losing -12.52% over the past week and -22.93% over the past quarter, though year-to-date performance is down -27.9%. Short-term trend indicators are mixed aligned (SMA20 -5.86%, SMA50 -9.75%, SMA200 0.69%). The stock’s 14-day RSI is 42.27 (neutral), while the ATR of 1.86 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -57.65% below its high and over 155.44% above its low. Average 10-day trading volume of 7.79 thousand shares is below the 3-month average of 23.55 thousand, indicating normal recent market interest.

Pelthos Therapeutics Inc. has 648.50 thousand shares outstanding. The public float is 616.46 thousand shares, elevated short interest at 0.83% of float. This equals 4.79 thousand shares. The short ratio is 0.03 days. Institutional investors hold 29.13% of the float. Insiders own 64.2%. Over the past six months, insider transactions show net selling. They sold 2.00 thousand shares across 1 transactions.

Pelthos Therapeutics Inc. generated EPS of $nan over the past year. Five-year average earnings growth is -87.88%. Analyst sentiment is bullish. Analyst rating data shows there are 3 Strong Buy ratings, 3 Buy ratings, 0 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $60.00 to $50.00. The high target offers 160.98% upside. The low target suggests 117.49% downside. The mean target is $55.67. This offers 142.15% upside. Pelthos Therapeutics Inc. earnings surprise history is a mixed track record. The quarter that ended November 13, 2025, missed forecasts by 691.04%. The prior quarter beat by 73.55%. Over the last six quarters, Apple has recorded several small beats. These include 73.55% in August 13, 2025.

Pelthos Therapeutics Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around -$2.85. This means the shares are trading below this model’s fair value.

Pelthos Therapeutics Inc. (AMEX:PTHS) closed at $22.99 USD, losing -$0.33 (-1.42%) from the previous close of $23.32. The stock is currently mid-range between its 52-week high and low $9.00 and $54.29. With a market capitalization of about $14.91 million, Pelthos Therapeutics Inc. is classified as a micro-cap and shows higher-than-market volatility (beta ~4.07). Key stats such as the average daily volume over the past year has been around 23.79 thousand shares, volume is running light vs its 52-week average. Headquartered in Durham, NC, Pelthos Therapeutics Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO Scott Plesha, the company employs approximately 4 people and listed since July 02, 2025. Pelthos Therapeutics Inc., a bio-pharmaceutical company, develops and commercializes therapeutic products to help patients with unmet treatment burdens.

Pelthos Therapeutics Inc. trades at a P/E ratio of -0.63, slightly below the S&P 500 average, with a price-to-sales ratio of 2.04 and a price-to-book ratio of 0.26 suggesting the stock is closer to book value. The P/FCF stands at -0.89, also above market averages.

Our AI price prediction model suggests that Pelthos Therapeutics Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected decline of -6.79%, with price expected at $21.43 by February 20, 2026, within a range of $19.53 to $23.24 3-Month Outlook: Projected rise of 232.06%, reaching $76.34 by May 06, 2026, with a range of $75.69 to $77.05. 1-Year Outlook: Projected loss of -100.0%, with price at $0.00 by February 05, 2027, within a range of $0.00 to $0.00.

Pelthos Therapeutics Inc. (NYSE:PTHS) shares are down -27.9% year-to-date currently trading near 52-week highs band. Short-term momentum has been negative over the last quarter, despite recent volatility. Valuation shows Pelthos Therapeutics Inc. trading at a premium to the broader market with a P/E of -0.63. Analyst sentiment is bullish, with the majority of ratings in Outperform territory and a mean price target of $55.67, suggesting 142.15% upside. Our AI forecast model points to short-term weakness (-6.79% over two weeks), a medium-term rise (232.06% over three months), and a longer-term loss (-100.0% over one year), with expected trading ranges indicating moderate volatility.